Borreliose Impfung
Lyme Vaccination

Steere AC, Sikand VK, Meurice F, et al. (1998) Vaccination against Lyme disease with recombinant _Borrelia burgdorferi_ outer-surface lipoprotein A with adjuvant. N Engl J Med 339, 209-215. http://www.nejm.org/doi/full/10.1056/NEJM199807233390401

Noble HB. (2000) 3 Suits Say Lyme Vaccine Caused Severe Arthritis. *New York Times*. June 13. http://www.nytimes.com/2000/06/13/science/3-suits-say-lyme-vaccine-caused-severe-arthritis.html Accessed 1/16/2014.

Molloy PJ, Berardi VP, Persing DH, Sigal LH. (2000) Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A Lyme disease vaccination. Clin Infect Dis **31,** 42–47.

Fawcett PT, Rose CD, Budd SM, Gibney KM. (2001) Eff ect of immunization with recombinant OspA on serologic tests for Lyme borreliosis. Clin Diagn Lab Immunol 8, 79–84.

Smith P. (2001) Remarks to Vaccines and Related Biological Products Advisory Committee, Bethesda, MD. http://www.lymediseaseassociation.org/index.php?option=com_content&view=article&id=262

GlaxoSmithKline. (2001) Package Insert – LYMErix Lyme Disease Vaccine (Recombinant OspA). http://us.gsk.com/products/assets/us_lymerix.pdf (131 KB). Accessed 1/16/2014.

Smith P, Gaito A, Marks DH. (2002) Transcript of FDA Lymerix meeting, Bethesda, MD. http://www.lymediseaseassociation.org/index.php/food-a-drug-administration-fda/532-lymerix-meeting

Lathrop SL, Ball R, Haber P et al. (2002) Adverse event reports following vaccination for Lyme disease: December 1998–July 2000. Vaccine. 20, 1603-1608. http://www.sciencedirect.com/science/article/pii/S0264410X0100500X Accessed 1/16/2014

Willett TA, Meyer AL, Brown EL, et al. (2004) An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc Natl Acad Sci U S A 101, 1303-1308.

Littman MP, Goldstein RE, Labato MA, et al. (2006) ACVIM Small Animal Consensus Statement on Lyme Disease in Dogs: Diagnosis, Treatment, and Prevention. J Vet Intern Med 20, 422-434.

Editorial (2006) When a vaccine is safe. Nature. 439, 509. http://www.nature.com/nature/journal/v439/n7076/full/439509a.html

McSweegan (2007) The Lyme vaccine : a cautionary tale. Epidemiol. Infect. 135, 9-10 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2870557/

Nigrovic LE, Thompson KM (2007) The Lyme vaccine: a cautionary tale. Epidemiol Infect. 135(1), 1-8. http://www.ncbi.nlm.nih.gov/pubmed/16893489

Stricker RB. (2008) Lymerix risks revisited. Microbe 3, 1–2.

Souayah N, Ajroud-Driss S, Sander HW, Brannagan TH, Hays AP, Chin RL. (2009) Small fiber neuropathy following vaccination for rabies, varicella or Lyme disease. Vaccine 27**,** 7322–25.

Nardelli DT, Munson EL, Callister SM, Schell RF. (2009) Human Lyme Disease Vaccines: Past and Future Concerns. Future Microbiology. 4(4), 457-469.

Seemanapalli SV, Xu Q, McShan K, Liang FT (2010) Outer Surface Protein C Is a Dissemination-Facilitating Factor of Borrelia burgdorferi during. Mammalian Infection. PLoS ONE 5(12), e15830. doi:10.1371/journal.pone.0015830

Marks DH. (2011) Neurological complications of vaccination with outer surface protein A (OspA). Int J Risk Saf Med **23,** 89–96.

Livey I, O'Rourke MO, Traweger A et al. (2011) A New Approach to a Lyme Disease Vaccine. Clinical Infectious Diseases 52(S3), 266–270

Kumar M, et al. (2011) Borrelia burgdorferi BBA52 is a potential target for transmission blocking Lyme disease vaccine. Vaccine doi:10.1016/j.vaccine.2011.09.035

Shen AK, Mead PS, Beard CB (2011) The Lyme Disease Vaccine—A Public Health Perspective. Lyme Disease Vaccine and Public Health 52(3), 247-252

Bhattacharya D, et al. (2011) Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease. Vaccine doi:10.1016/j.vaccine.2011.07.100

Allen C. Steere AC, Elise E. Drouin EE, and Lisa J. Glickstein LJ (2011) Relationship between Immunity to Borrelia burgdorferi Outer-surface Protein A (OspA) and Lyme Arthritis. Clinical Infectious Diseases 52(S3), 259–S265

Steere AC, Drouin EE, Glickstein LJ, (2011) Relationship between Immunity to _Borrelia burgdorferi_ Outer-surface Protein A (OspA) and Lyme Arthritis. Clinical Infectious Diseases 52(S3), 259-265. http://cid.oxfordjournals.org/content/52/suppl_3/s259.full.pdf+html

Poland GA. (2011) Vaccines against Lyme disease: What happened and what lessons can we learn? Clin Infect Dis. 52 (Suppl 3), s253-8. doi:10.1093/cid/ciq116. http://cid.oxfordjournals.org/content/52/suppl_3/s253.long

Krupka M, Masek J, Bartheldyova E et al. (2012) Enhancement of immune response towards non-lipidized Borrelia burgdorferi recombinant OspC antigen by binding onto the surface of metallochelating nanoliposomes with entrapped lipophilic derivatives of norAbuMDP, Journal of Controlled Release, doi:10.1016/j.jconrel.2012.02.017

Bensaci M, Bhattacharya D et al. (2012) Oral vaccination with vaccinia virus expressing the tick antigen subolesin inhibits tick feeding and transmission of Borrelia burgdorferi. Vaccine 30, 6040–6046

Leventhal JS, Berger EM, Brauer JA et al. (2012) Hypersensitivity Reactions to Vaccine Constituents: A Case Series and Review of the Literature. DERMATITIS, 23(3), 102-109

Aronowitz RA (2012) The Rise and Fall of the Lyme Disease Vaccines: A Cautionary Tale for Risk Interventions in American Medicine and Public Health. The Milbank Quarterly, 90(2), 250–277 http://www.ncbi.nlm.nih.gov/pubmed/22709388 http://www.aldf.com/pdf/Aronowitz_The_Rise_and_Fall_of_Lyme_Vaccines.pdf

de la Fuente J, Merino O. (2013) Vaccinomics, the new road to tick vaccines. Vaccine. http://dx.doi.org/10.1016/j.vaccine.2013.10.049

Wressnigg N, Pollabauer E-M, Aichinger G, et al. (2013) Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis 13, 680–89.

Lantos PM. (2013) Lyme disease vaccination: are we ready to try again? Lancet Infect Dis 13, 643–44. http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2813%2970085-9/fulltext

Plotkin SA (2013) Bring Back the Lyme Vaccine. http://www.nytimes.com/2013/09/19/opinion/bring-back-the-lyme-vaccine.html

Wressnigg N, Pöllabauer EM, Aichinger G (2013) **Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults**: a double-blind, randomised, dose-escalation phase 1/2 trial www.thelancet.com/infection Published online May 10, 2013

http://dx.doi.org/10.1016/S1473-3099(13)70110-5
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2813%2970110-5/abstract
„We investigated the safety and immunogenicity of adjuvanted and non-adjuvanted vaccines containing protective epitopes from *Borrelia* species outer surface protein A (OspA) serotypes in healthy adults."

Phase 1/2 Lyme Vaccine Study http://clinicaltrials.gov/show/NCT01504347 Accessed 1/16/2014.

Wressnigg N, Barrett PN, Pöllabauer E-M et al. (2014) **A Novel Multivalent OspA 1 Vaccine against Lyme Borreliosis is Safe and Immunogenic in an Adult Population Previously Infected with Borrelia burgdorferi sensu lato**. CVI Accepts, published online ahead of print on 3 September 2014 Clin. Vaccine Immunol. doi:10.1128/CVI.00406-14
« We have developed a novel multivalent OspA vaccine, which comprises three recombinant OspA antigens, each containing protective epitopes from two different OspA serotypes i.e. OspA serotypes 1 and 2 (*B.burgdorferi* s.s. and *B. afzelii*); 5 and 3 (both *B. garinii*); and 6 and 4 (*B. garinii* and *B. bavariensis*) *(22)*. The multivalent vaccine is designed to protect against all major disease–causing *Borrelia* species in the US (OspA-1) and Europe (OspA 1-6), and potentially globally".

Stricker RB, Johnson L (2014) **Lyme disease vaccination: safety first.** The Lancet Infectious Diseases, 14(1), 12 doi:10.1016/S1473-3099(13)70319-0 Cite or Link Using DOI **Inclusively authors reply**. http://download.thelancet.com/pdfs/journals/laninf/PIIS1473309913703190.pdf?id=jaaR4JzkdCyL_9u5IYAEu

Comstedt P, Hanner M, Schüler W et al. (2014) **Design and Development of a Novel Vaccine for Protection against Lyme Borreliosis**. PLOSone. 9(11), e113294
http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0113294&representation=PDF
http://www.plosone.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0113294&representation=PDF

Comstedt P, Hanner M, Schüler W et al. (2015) **Characterization and optimization of a novel vaccine for protection against Lyme borreliosis.** Vaccine. pii: S0264-410X(15)01099-3. doi: 10.1016/j.vaccine.2015.07.095. http://www.ncbi.nlm.nih.gov/pubmed/26277070

Zhao H, Bao FF, Liu A (2017) **Safety, immunogenicity, and efficacy of *Borrelia burgdorferi* outer surface protein A (OspA) vaccine: A meta-analysis.** J Infect Dev Ctries 11(1), 1-9. doi:10.3855/jidc.7999 https://www.ncbi.nlm.nih.gov/pubmed/11433064

➔ **The History of the Lyme Vaccines**
http://www.historyofvaccines.org/content/articles/history-lyme-disease-vaccine

Impfstoffzusätze, Kontroversen und Miss-Verständnisse, Vaccine additives, controversies and misunderstandings

Sen S, Cloete Y, Hassan K, Buss P (2001) **Adverse events following vaccination in premature infants**, Acta Paediatrica, Aug;90(8):916-20.

Bonhoeffer J, Siegrist C-A, Heath PT (2006) **Immunisation of premature infants**, Archives of Disease in Childhood, Nov; 91(11), 929–935. DOI: 10.1136/adc.2005.086306

DeMeo SD, Raman SR, Hornik ChP et al. (2015) **Adverse Events After Routine Immunization of Extremely Low Birth Weight Infants**, JAMA Pediatrics, 2015 Aug 1; 169(8), 740–745. DOI: **10.1001/jamapediatrics.2015.0418**

Gherardi RK, Eidi H, Crépeaux G et al. (2015) **Biopersistence and brain translocation of aluminum adjuvants of vaccines.** Front. Neurol, doi: 10.3389/fneur.2015.00004
http://journal.frontiersin.org/Journal/10.3389/fneur.2015.00004/full

Gatti AM, Montanari S (2017) **New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination.** International Journal of Vaccines and Vaccination 4(1), 00072
http://www.whale.to/c/vaxcontaminants_IJVV-04-00072.pdf

Adams M (2017) **VACCINE RAGE explains why the world is going INSANE**
https://vimeo.com/216200564

Ortel Ch. (2017) **Truth About Vaccines.**
https://sites.google.com/site/lymevaccine/truth-about-vaccines-series

Mawson AR, Ray BD, Bhuiyan AR, Jacob B (2017) **Pilot comparative study on the health of vaccinated and unvaccinated 6- to 12- year old U.S children**, Journal of Translational Science, DOI: 10.15761/JTS.1000186

Jaxen J (2017) **Vaccinated Vs. Unvaccinated Pilot Study: Early Vaccination Sees Exponential Increase in Chronic Disorders.**
http://www.greenmedinfo.com/blog/vaccinated-vs-unvaccinated-pilot-study-early-vaccination-sees-exponential-increas

Vaccination - to reduce population! (Bill Gates admits)
https://www.youtube.com/watch?v=pjj4Iq-rsNg

Bill Gates says Reduce Population 4 TIMES!!
https://www.youtube.com/watch?v=8BobKXkrt8M
https://www.youtube.com/watch?v=8BobKXkrt8M#t=156.8733235

R.E.G.E.T http://www.regret.ie/